Congenital aniridia beyond black eyes: From phenotype and novel genetic mechanisms to innovative therapeutic approaches.
Congenital aniridia
Foveal hypoplasia
Gene therapy
Next-generation sequencing
PAX6
Whole-genome sequencing
Journal
Progress in retinal and eye research
ISSN: 1873-1635
Titre abrégé: Prog Retin Eye Res
Pays: England
ID NLM: 9431859
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
03
07
2022
revised:
27
09
2022
accepted:
03
10
2022
medline:
10
7
2023
pubmed:
25
10
2022
entrez:
24
10
2022
Statut:
ppublish
Résumé
Congenital PAX6-aniridia, initially characterized by the absence of the iris, has progressively been shown to be associated with other developmental ocular abnormalities and systemic features making congenital aniridia a complex syndromic disorder rather than a simple isolated disease of the iris. Moreover, foveal hypoplasia is now recognized as a more frequent feature than complete iris hypoplasia and a major visual prognosis determinant, reversing the classical clinical picture of this disease. Conversely, iris malformation is also a feature of various anterior segment dysgenesis disorders caused by PAX6-related developmental genes, adding a level of genetic complexity for accurate molecular diagnosis of aniridia. Therefore, the clinical recognition and differential genetic diagnosis of PAX6-related aniridia has been revealed to be much more challenging than initially thought, and still remains under-investigated. Here, we update specific clinical features of aniridia, with emphasis on their genotype correlations, as well as provide new knowledge regarding the PAX6 gene and its mutational spectrum, and highlight the beneficial utility of clinically implementing targeted Next-Generation Sequencing combined with Whole-Genome Sequencing to increase the genetic diagnostic yield of aniridia. We also present new molecular mechanisms underlying aniridia and aniridia-like phenotypes. Finally, we discuss the appropriate medical and surgical management of aniridic eyes, as well as innovative therapeutic options. Altogether, these combined clinical-genetic approaches will help to accelerate time to diagnosis, provide better determination of the disease prognosis and management, and confirm eligibility for future clinical trials or genetic-specific therapies.
Identifiants
pubmed: 36280537
pii: S1350-9462(22)00093-3
doi: 10.1016/j.preteyeres.2022.101133
pii:
doi:
Substances chimiques
PAX6 Transcription Factor
0
Eye Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101133Subventions
Organisme : NEI NIH HHS
ID : R01 EY028597
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declarations of competing interest None. The three layers of the cornea are defined: the corneal endothelium (CEnd) deriving from the first set of neural crest cells/POM cells, the corneal stroma (CS) deriving from the second wave of NC cells/POM cells and the corneal epithelium (CE) developing from the outer surface ectoderm. The third wave of NC cells/POM cells arrives at the angle of the future cornea and the periphery of the optic cup and contributes to pupillary membrane and iris stroma development. From the periphery of the optic cup will then originate the pigmented epithelium and the smooth muscle of the iris. HV (hyaloid vessels, tunica vasculosa lentis).